Skip to main content
SpringerLink
Log in

Palliative Chirurgie maligner Schilddrüsentumoren

  • Chapter
  • First Online:
Palliative Viszeralchirurgie

  • 1375 Accesses

Zusammenfassung

Die Krankheitsdynamik maligner Schilddrüsentumoren variiert stark. Daher kann die palliative Phase unterschiedlich lang sein. So entsteht ein Patientenkollektiv, das zwar nicht mehr kurativ behandelt werden kann, aber unter palliativer Therapie eine respektable Lebenserwartung hat. Therapeutisches Vorgehen sowie die Einschätzung der palliativen Situation hängen stark vom vorliegenden Tumortyp ab. Die moderne Onkologie bietet neben den klassischen Therapieformen, bestehend aus chirurgischer Resektion mit anschließender Radiojodtherapie, weitere Optionen, wie Therapie mit Tyrosinkinaseinhibitoren bei entstandener Jodresistenz, an. Bei Beteiligung umliegender Organe treten frühzeitig Beeinträchtigungen wichtiger Lebensfunktionen auf. Drohender Autonomieverlust und Versorgungsbedürftigkeit der Patienten können präventive palliativchirurgische Maßnahmen notwendig machen, um die Lebensqualität der Patienten zu unterstützen. Art und Umfang chirurgischer Maßnahmen in dieser Grenzzone ist bei den verschiedenen Formen des Schilddrüsenkarzinoms unterschiedlich zu bewerten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Agrawal N et al (2017) Indications and extent of central neck dissection for papillary thyroid cancer: an American head and neck society consensus statement. Head Neck 39(7):1269–1279

    Article  PubMed  Google Scholar 

  • Ahmadi S et al (2016) Hürthle cell carcinoma: current perspectives. Onco Targets Ther 9:6873–6884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ahmend et al (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 165:315–322

    Article  Google Scholar 

  • Brose MS et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced, double-blind, phase 3 trial. Lancet 384(9940):319–328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cabanillas ME et al (2016a) Thyroid cancer. Lancet 388(10061):2783–2795

    Article  CAS  PubMed  Google Scholar 

  • Cabanillas ME et al (2016b) Anaplastic thyroid carcinoma: treatment in the age of molecular targeted therapy. J Oncol Pract 12(6):511–519

    Article  PubMed  Google Scholar 

  • Chintakuntlawar AV et al (2017) Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study. J Clin Endocrinol Metab 102(6):1943–1950

    Google Scholar 

  • Copland JA et al (2006) Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25:2304–2317

    Article  CAS  PubMed  Google Scholar 

  • Dralle H (2014) Endokrine Chirurgie. Evidenz und Erfahrung – Individualisierte Medizin in der klinischen Praxis. Schattauer, Stuttgart

    Google Scholar 

  • Dralle H et al (2013) German association of endocrine surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg 398(3):403–409

    Article  PubMed  Google Scholar 

  • Durante C et al (2006) Long-term outcome of 444 patients with distant metastases from papillary and folliculary thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91(8):2892–2899

    Article  CAS  PubMed  Google Scholar 

  • Elisei R et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639–3646

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ernani V et al (2016) Systemic treatment and management approaches for medullary thyroid cancer. Cancer Treat Rev 50:89–98

    Article  PubMed  Google Scholar 

  • Fialkowsky E et al (2008) Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 32:754–765

    Article  Google Scholar 

  • Gibson W et al (2017) Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer. Clin Cancer Res 23(9):2367–2373

    Article  CAS  PubMed  Google Scholar 

  • Haigh PI et al (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irridation is associated with prolonged survival. Cancer 91(12):2335–2342

    Article  CAS  PubMed  Google Scholar 

  • Haugen BR et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133

    Article  PubMed  PubMed Central  Google Scholar 

  • Higashiyama T et al (2010) Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20(1):7–14

    Article  CAS  PubMed  Google Scholar 

  • Ito Y et al (2017a) Prognostic significance of the proportion of all cell components in papillary thyroid carcinoma. World J Surg 41:742–747

    Article  PubMed  Google Scholar 

  • Ito Y et al (2017b) Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and Anaplastic thyroid carcinoma. Thyroid 27(9):1142–1148

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jin LX et al (2016) Surgery for lymph node metastases of medullary thyroid carcinoma: a review. Cancer 122(3):358–366

    Article  PubMed  Google Scholar 

  • Kebebew E et al (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103(7):1330–1335

    Article  PubMed  Google Scholar 

  • Keutgen XM et al (2015) Management of anaplastic thyroid cancer. Gland Surg 4(1):44–51

    PubMed  PubMed Central  Google Scholar 

  • Kim BH et al (2016) Recent updates on the management of medullary thyroid carcinoma. Endocrinol Metab (Seoul) 31(3):392–399

    Article  CAS  Google Scholar 

  • Kim SW et al (2017) Intraoperative real-time localization of parathyroid gland with near infrared fluorescence imaging. Gland Surg 6(5):516–524

    Article  PubMed  PubMed Central  Google Scholar 

  • Lavazza M et al (2016) Indocaynine green-enhanced fluorescence for assessing parathyroid perfusion during thyroidectomy. Gland Surg 5(5):512–521

    Article  PubMed  PubMed Central  Google Scholar 

  • Leite AK et al (2017) Death related to pulmonary metastasis in patients with differentiated thyroid cancer. Endocr Pract 23(1):72–78

    Article  PubMed  Google Scholar 

  • Li F et al (2015) BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocr Relat Cancer 22(2):159–168

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lim SM et al (2013) A multicenter phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol 24(12):3089–3094

    Article  CAS  PubMed  Google Scholar 

  • Liu et al (2014) TERT promoter mutations and their associations with BRAFV600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 99(6):1130–1136

    Article  Google Scholar 

  • Lorusso L et al (2016) Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced and progressive thyroid cancer. Onco Targets Ther 9:6467–6477

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lubitz CC et al (2014) Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. Thyroid 24(6):958–965

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mazzaferri EL et al (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97(5):418–428

    Article  CAS  PubMed  Google Scholar 

  • Meijer JA et al (2010) Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol 72:534–542

    Article  CAS  Google Scholar 

  • Mitchell AL et al (2016) Management of thyroid cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol 130(S2):S150–S160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Molinaro E et al (2017) Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nature Rev, advanced online publication. https://doi.org/10.1038/nrendo.2017.76

    Article  CAS  PubMed  Google Scholar 

  • Nixon IJ et al (2012) The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 22:884–889

    Article  PubMed  PubMed Central  Google Scholar 

  • Onoda N et al (2016) The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study. Thyroid 26(9):1293–1299

    Article  CAS  PubMed  Google Scholar 

  • Pantvaidya G et al (2017) Morbidity of central compartment clearance: comparison of lesser versus complete clearance in patients with thyroid cancer. J Cancer Res Ther 13(1):102–106

    Article  CAS  PubMed  Google Scholar 

  • Perri F et al (2011) Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2(3):150–157

    Article  PubMed  PubMed Central  Google Scholar 

  • Poisson T et al (2010) 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 37:2277–2285

    Article  PubMed  Google Scholar 

  • Porterfield JR et al (2009) Thoracic metastasectomy for thyroid malignancies. Eur J Cardiothorac Surg 36(1):155–158

    Article  PubMed  PubMed Central  Google Scholar 

  • Prasongsook N et al (2017) Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab 102(12):4506–4514

    Article  PubMed  Google Scholar 

  • Pusztaszeri M et al (2017) Update on the cytologic features of papillary thyroid carcinoma variants. Diagn Cytopathol 45(8):714–730

    Article  PubMed  Google Scholar 

  • Randle RW et al (2017) Trends in the presentation, treatment and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 161(1):137–146

    Article  PubMed  Google Scholar 

  • Robenshtok E et al (2012) Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. J Clin Endocrinol Metab 97(8):2706–2713

    Article  CAS  PubMed  Google Scholar 

  • Roh JL et al (2011) Central compartment reoperation for recurrent/persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia. Ann Surg Oncol 18:1312–1318

    Article  PubMed  Google Scholar 

  • Rondeau G, Fish S, Hann LE et al (2011) Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. Thyroid 21:845–853

    Article  PubMed  Google Scholar 

  • Rosove MH et al (2013) BRAF V600E inhibition in anaplastic thyroid cancer. NEJM 368(7):684–685

    Article  CAS  PubMed  Google Scholar 

  • Sabra MM et al (2013) Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endicrinol Metab 98(5):E829–E836

    Article  CAS  Google Scholar 

  • Schlumberger M et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. NEJM 372(7):621–630

    Article  PubMed  Google Scholar 

  • Schmid KW et al (2015) Lymphknoten- und Organmetastasen des Schilddrüsenkarzinoms. Pathologe 36:171–175

    Article  PubMed  Google Scholar 

  • Shaha AR et al (1997) Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 174:474–476

    Article  CAS  PubMed  Google Scholar 

  • Shen X et al (2017) A six-genotype genetic prognostic model for papillary thyroid cancer. Endocr Relat Cancer 24(1):41–52

    Article  PubMed  Google Scholar 

  • Shi X et al (2016) Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab 101(1):264–274

    Article  CAS  PubMed  Google Scholar 

  • Shin DH et al (1993) Pathologic staging of papillary carcinoma of the thyroid with airway invasion based on the anatomic manner of extension to the trachea: a clinicopathologic study based on 22 patients who underwent thyroidectomy and airway resection. Hum Pathol 24:866–870

    Article  CAS  PubMed  Google Scholar 

  • Shirley LA et al (2017) The role of central neck lymph node dissection in the management of papillary thyroid cancer. Front Oncol 7(122):1–7

    Google Scholar 

  • Sk2-Leitlinie zur operativen Therapie maligner Schilddrüsenerkrankungen (2012). https://www.dgav.de/fileadmin/media/texte_pdf/caek/Leitlinie_Maligne_Schilddruesenerkrankungen_Operative_Therapie_2012-11.pdf. Zugegriffen am 27.11.2018

  • Smallridge RC et al (2013) Efatutazone, an oral PPRAGamma agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab 98(6):2392 ff

    Article  Google Scholar 

  • Sound S et al (2015) Utility of indocyanine green fluorescence imaging for intraoperative localization in reoperative parathyroid surgery. Surg Innov Oct:1–6

    Google Scholar 

  • Su SY et al (2016) Well-differentiated thyroid cancer with aerodigestive tract invasion: long-term control and functional outcomes. Head Neck 38(1):72–78

    Article  PubMed  Google Scholar 

  • Su A et al (2018) Effect of autotransplantation of a parathyroid gland on hypoparathyroidism after total thyroidectomy. Endocr Connect 7(2):286–294

    Article  CAS  PubMed  Google Scholar 

  • Tiedje V et al (2017) NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. Oncotarget 8(26):42613–42620

    Article  PubMed  PubMed Central  Google Scholar 

  • Wagle N et al (2014) Response and acquired resistance to everolimus in anaplastic thyroid cancer. NEJM 371(15):1426–1433

    Article  PubMed  Google Scholar 

  • Wang LY et al (2016) Operative management of locally advanced, differentiated thyroid cancer. Surgery 160(3):738–746

    Article  PubMed  PubMed Central  Google Scholar 

  • Wells SA et al (2012) Vandetanib inpatients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134–141

    Article  CAS  PubMed  Google Scholar 

  • Wells SA et al (2015) Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567–610

    Article  PubMed  PubMed Central  Google Scholar 

  • Wendler J et al (2016) Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: a result of a multicenter study in Germany. Eur J Endocrinol 175:521–529

    Article  CAS  PubMed  Google Scholar 

  • Xu et al (2016a) Clinicopathologic features of fatal non-anaplastic follicular cell-derived thyroid carcinomas. Thyroid 26(11):1588–1597

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xu JY et al (2016b) Bone metastases and skeletal-related events in medullary thyroid carcinoma. J Clin Endocrinol Metab 101(12):4871–4877

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xu B et al (2016c) Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma. Endocr Pathol 27:205–2012

    Article  CAS  PubMed  Google Scholar 

  • Yang Z et al (2017a) Comparison of survival outcomes following postsurgical radioactive iodine versus external beam radiation in stage IV differentiated thyroid carcinoma. Thyroid 27(7):944–952

    Article  CAS  PubMed  Google Scholar 

  • Yang X et al (2017b) TERT Promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer. J Nucl Med 58(2):258–265

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Allgemein-, Visceral- und Endokrine Chirurgie, Alexianer Krefeld GmbH, Krefeld, Deutschland

    Petra Kühn

Authors
  1. Petra Kühn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Petra Kühn .

Editor information

Editors and Affiliations

  1. Universitätsmedizin Göttingen, Klinik für Allgemein-, Viszeral- und Kinderchirurgie, Göttingen, Germany

    Michael Ghadimi

  2. Klinik für Allgemein, Viszeral- und Gefäßchirurgie, DRK-Kliniken Nordhessen, Kassel, Germany

    Kia Homayounfar

  3. Klinik und Poliklinik für Allgemein-, Universitätsklinikum Bonn Klinik und Poliklinik für Allgemein-, Bonn, Germany

    Jörg C. Kalff

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kühn, P. (2019). Palliative Chirurgie maligner Schilddrüsentumoren. In: Ghadimi, M., Homayounfar, K., Kalff, J. (eds) Palliative Viszeralchirurgie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57362-4_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57362-4_22

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57361-7

  • Online ISBN: 978-3-662-57362-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation